Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at ...

Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find ...

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the ...

Malaysia said on Tuesday it expects its COVID-19 vaccination plan to proceed as scheduled after the government received assurances from the EU and Belgian ambassadors about the delivery of Pfizer's ...

In response to a call from President Donald Trump to make the positive impact of Covid-19 vaccines public, drug giant Pfizer posted a collection of more than 200 news releases and statements and 27 ...

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue ...

Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock ...